Skip to main content

Table 6 Risk of colorectal cancer, overall and according to clinicopathological factors, in relation to oral contraceptive (OC) use

From: Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability

Tumour subgroups OC use n HR crude p HR adjusted p
CRC No 194 1.00   1.00  
OC 107 0.56(0.44-0.71) <0.001 1.05(0.80-1.37) 0.738
T stage 1 & 2 No 45 1.00   1.00  
OC 17 0.39(0.22-0.68) 0.001 0.69(0.37-1.28) 0.239
T stage 3 & 4 No 127 1.00   1.00  
OC 77 0.62(0.47-0.82) 0.001 1.21(0.87-1.67) 0.254
N0 No 105 1.00   1.00  
OC 46 0.45(0.32-0.63) <0.001 0.82(0.56-1.22) 0.328
N1 & N2 No 60 1.00   1.00  
OC 45 0.78(0.52-1.13) 0.176 1.36(0.88-2.11) 0.173
M0 No 150 1.00   1.00  
OC 85 0.58(0.44-0.75) <0.001 1.05(0.78-1.42) 0.744
M1 No 38 1.00   1.00  
OC 17 0.46(0.26-0.81) 0.007 0.90(0.47-1.70) 0.734
beta-catenin+ No 105 1.00   1.00  
OC 51 0.50(0.35-0.70) <0.001 0.97(0.66-1.41) 0.853
beta-catenin− No 61 1.00   1.00  
OC 42 0.70(0.47-1.04) 0.076 1.31(0.84-2.05) 0.232
cyclin D1+ No 138 1.00   1.00  
OC 75 0.55(0.42-0.74) <0.001 1.16(0.85-1.60) 0.351
cyclin D1− No 30 1.00   1.00  
OC 15 0.51(0.27-0.94) 0.032 0.63(0.32-1.27) 0.199
p53+ No 81 1.00   1.00  
OC 46 0.58(0.41-0.83) 0.003 1.06(0.70-1.60) 0.744
p53− No 88 1.00   1.00  
OC 45 0.52(0.36-0.74) <0.001 1.04(0.70-1.56) 0.840
MSI No 28 1.00   1.00  
OC 17 0.62(0.34-1.13) 0.117 1.78(0.92-3.47) 0.088
MSS No 136 1.00   1.00  
  OC 74 0.56(0.42-0.74) <0.001 0.98(0.71-1.36) 0.912
  1. Adjusted for age, bmi, educational level, smoking habits and alcohol consumption.